Yes I think the results (RA) will be very promising,the one that will really move Mesoblast will be the interim analysis (due first quarter 2016) on the CHF trial which has been going now for almost 2 years.If the results show good efficacy the stock will sky rocket, no question.The 60 patient phase 2 trial carried out by NHI on stage 4 (CHF) has shown the greatest improvement in patient outcomes which bodes well for the upcoming interim analysis.
Stem Cell Sector, page-27
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |